Clinical Trial Update: Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a tumor antigen-sensitized dendritic cell vaccine as adjuvant therapy for esophageal cancer has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Tumor antigen-sensitized dendritic cell vaccine (dendritic cell vaccine)

Snippet

Sponsor: Sichuan University | Conditions: Carcinoma, Esophagus Cancer | Phase 1 | Status: COMPLETED